293 related articles for article (PubMed ID: 19856421)
21. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas.
Ciampa A; Fanger G; Khan A; Rock KL; Xu B
Cancer; 2004 Dec; 102(6):368-72. PubMed ID: 15558786
[TBL] [Abstract][Full Text] [Related]
22. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
[TBL] [Abstract][Full Text] [Related]
23. Does ampullary carcinoma arise from distended glands in the papilla of Vater?
Sonoue H; Suda K; Nobukawa B; Abe H; Arakawa A; Hirai S; Matsumoto T
J Hepatobiliary Pancreat Surg; 2008; 15(2):161-8. PubMed ID: 18392709
[TBL] [Abstract][Full Text] [Related]
24. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary.
Cao D; Ji H; Ronnett BM
Int J Gynecol Pathol; 2005 Jan; 24(1):67-72. PubMed ID: 15626919
[TBL] [Abstract][Full Text] [Related]
25. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
Comin CE; Saieva C; Messerini L
Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
[TBL] [Abstract][Full Text] [Related]
26. A panel of immunohistochemical stains assists in the distinction between ovarian and renal clear cell carcinoma.
Cameron RI; Ashe P; O'Rourke DM; Foster H; McCluggage WG
Int J Gynecol Pathol; 2003 Jul; 22(3):272-6. PubMed ID: 12819395
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
Chu PG; Schwarz RE; Lau SK; Yen Y; Weiss LM
Am J Surg Pathol; 2005 Mar; 29(3):359-67. PubMed ID: 15725805
[TBL] [Abstract][Full Text] [Related]
28. Cytokeratin expression profiling in gastric carcinoma: clinicopathologic significance and comparison with tumor-associated molecules.
Takami H; Sentani K; Matsuda M; Oue N; Sakamoto N; Yasui W
Pathobiology; 2012; 79(3):154-61. PubMed ID: 22286119
[TBL] [Abstract][Full Text] [Related]
29. Expression profile of mucins in ovarian mucinous tumors: distinguishing primary ovarian from metastatic tumors.
Wang J; El-Bahrawy MA
Int J Gynecol Pathol; 2014 Mar; 33(2):166-75. PubMed ID: 24487472
[TBL] [Abstract][Full Text] [Related]
30. Value of immunohistochemistry in confirming undifferentiated ovarian carcinomas.
Georgescu CV; Florescu M; Simionescu C
Rom J Morphol Embryol; 1999-2004; 45():133-42. PubMed ID: 15847387
[TBL] [Abstract][Full Text] [Related]
31. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary.
Tornos C; Soslow R; Chen S; Akram M; Hummer AJ; Abu-Rustum N; Norton L; Tan LK
Am J Surg Pathol; 2005 Nov; 29(11):1482-9. PubMed ID: 16224215
[TBL] [Abstract][Full Text] [Related]
32. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites.
Lagendijk JH; Mullink H; Van Diest PJ; Meijer GA; Meijer CJ
Hum Pathol; 1998 May; 29(5):491-7. PubMed ID: 9596273
[TBL] [Abstract][Full Text] [Related]
33. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT).
Ueda M; Miura Y; Kunihiro O; Ishikawa T; Ichikawa Y; Endo I; Sekido H; Togo S; Shimada H
Hepatogastroenterology; 2005; 52(62):398-403. PubMed ID: 15816444
[TBL] [Abstract][Full Text] [Related]
34. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum.
Hashi A; Yuminamochi T; Murata S; Iwamoto H; Honda T; Hoshi K
Int J Gynecol Pathol; 2003 Oct; 22(4):374-7. PubMed ID: 14501819
[TBL] [Abstract][Full Text] [Related]
35. Identification of HLA-A*0201- and A*2402-restricted epitopes of mucin 5AC expressed in advanced pancreatic cancer.
Yamazoe S; Tanaka H; Iwauchi T; Yoshii M; Ito G; Amano R; Yamada N; Sawada T; Ohira M; Hirakawa K
Pancreas; 2011 Aug; 40(6):896-904. PubMed ID: 21697763
[TBL] [Abstract][Full Text] [Related]
36. MUC2 is a molecular marker for pseudomyxoma peritonei.
O'Connell JT; Hacker CM; Barsky SH
Mod Pathol; 2002 Sep; 15(9):958-72. PubMed ID: 12218214
[TBL] [Abstract][Full Text] [Related]
37. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.
Adsay NV; Basturk O; Cheng JD; Andea AA
Semin Radiat Oncol; 2005 Oct; 15(4):254-64. PubMed ID: 16183479
[TBL] [Abstract][Full Text] [Related]
38. Sialylated MUC1 mucin expression in normal pancreas, benign pancreatic lesions, and pancreatic ductal adenocarcinoma.
Masaki Y; Oka M; Ogura Y; Ueno T; Nishihara K; Tangoku A; Takahashi M; Yamamoto M; Irimura T
Hepatogastroenterology; 1999; 46(28):2240-5. PubMed ID: 10521973
[TBL] [Abstract][Full Text] [Related]
39. Unique expression of MUC3, MUC5AC and cytokeratins in salivary gland carcinomas.
Lee JH; Lee JH; Kim A; Kim I; Chae YS
Pathol Int; 2005 Jul; 55(7):386-90. PubMed ID: 15982212
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update.
Baker PM; Oliva E
Int J Gynecol Pathol; 2005 Jan; 24(1):39-55. PubMed ID: 15626916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
